In addition to NSCLC, ACOX2 has also been shown to be dysregulated in various cancers, including breast cancer [86,87], prostate cancer [88,89], and hepatocellular carcinoma [90], and targeting peroxisomes is an emerging potential therapeutic approach including NSCLC [91,92,93]. This evidence concerns the gene ACOX2 and prostate carcinoma.